Featured Research

from universities, journals, and other organizations

Age Alone Should Not Be Used To Determine Whether To Treat Prostate Cancer With Hormones, Research Suggests

Date:
September 30, 2008
Source:
Fox Chase Cancer Center
Summary:
Concerns regarding the association of hormone therapy used to treat prostate cancer with cardiovascular disease in some older men may lead doctors to forgo hormone treatment solely on the basis of age. But a new study shows that men over age 70 with high-risk prostate cancer lived longer and experienced increases in PSA less frequently when treated with long-term androgen deprivation therapy.

Concerns regarding the association of hormone therapy used to treat prostate cancer with cardiovascular disease in some older men may lead doctors to forgo hormone treatment solely on the basis of age. But a new study by physicians at Fox Chase Cancer Center shows that men over age 70 with high-risk prostate cancer lived longer and experienced increases in PSA less frequently when treated with long-term androgen deprivation therapy.

The benefit of long-term (i.e. 2-3 years) androgen deprivation therapy has been established in high-risk prostate cancer patients in several prospective, randomized clinical trials. However, concern that androgen deprivation therapy may result in cardiovascular disease, particularly in older patients men with certain risk factors for cardiovascular disease, has led investigators to question its role in older men.

"Several studies have demonstrated a survival benefit when androgen deprivation therapy is used along with radiotherapy in men with high-risk, clinically localized prostate cancer," said the study's lead author, Joshua Silverman, MD, PhD, a resident in the Department of Radiation Oncology at Fox Chase. "What we did not know until now is whether this benefit outweighs the risks of cardiovascular and metabolic adverse effects from androgen deprivation therapy."

In this retrospective study presented September 24 at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology, researchers identified men with prostate cancer that was confined to the prostate, but considered high-risk (i.e. pre-treatment PSA ≥ 20, Gleason score 8-10, or larger tumors palpable during digital rectal exam) and looked at outcomes with and without the use of hormone therapy.

"We know the risk of distant metastasis, recurrence and death are higher when androgen deprivation therapy is not part of radiation treatment," said Silverman. "We wanted to see if age should be a determining factor for treatment with hormone suppression."

Researchers found the overall rate of biochemical failure (i.e., a rise in the PSA level) is lower for men who received hormone therapy regardless of age. A rise in PSA can indicate the recurrence or spread of prostate cancer and often leads to more testing and more aggressive treatments.

"We saw the greatest advantage of hormone therapy among men who received a longer duration of androgen deprivation therapy, including those with pre-existing cardiovascular and metabolic concerns," said Silverman.

A longer duration (more than 12 months) of hormone therapy resulted in a greater overall survival for all men (≤12 months-87 percent, ≥ 12 months-98 percent; p=0.02) including in men older than 70 (≤12 months-80 percent, ≥ 12 months-98 percent; p=0.03).

Men under 70 who received hormone therapy had a greater 5 year overall survival rate (96 percent v 91 percent; p0.03) than did men over 70 (89 percent v. 86 percent; 0.17).

"This may be explained in part by a trend toward greater pre-existing cardiovascular concerns in men over age 70," Silverman said.

Still, Silverman said, "We concluded that age alone should not be considered a contraindication to hormone treatment in high-risk patients. While co-morbidities may influence clinical decision-making regarding androgen deprivation therapy, we do not have enough data to select patients who should or should not receive treatment of a shorter duration based on age alone."

"One weakness of this study is selection bias because men in this retrospective analysis were not randomized to androgen deprivation therapy." Silverman said, "We still need to continue our careful consideration of each individual's health before recommending androgen deprivation therapy."

Silverman added that the study does not address the impact hormones may have on a man's quality of life. The adverse effects of hormones include muscle loss, cognitive issues, loss of libido, and osteoporosis.

The study was funded by Fox Chase. Other authors include Karen Ruth, Eric M. Horwitz, Alan Pollack, David Y. T. Chen, and Mark K. Buyyounouski of Fox Chase.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Age Alone Should Not Be Used To Determine Whether To Treat Prostate Cancer With Hormones, Research Suggests." ScienceDaily. ScienceDaily, 30 September 2008. <www.sciencedaily.com/releases/2008/09/080924124533.htm>.
Fox Chase Cancer Center. (2008, September 30). Age Alone Should Not Be Used To Determine Whether To Treat Prostate Cancer With Hormones, Research Suggests. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2008/09/080924124533.htm
Fox Chase Cancer Center. "Age Alone Should Not Be Used To Determine Whether To Treat Prostate Cancer With Hormones, Research Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/09/080924124533.htm (accessed April 17, 2014).

Share This



More Health & Medicine News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins